The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and
With the European Commission looking to formally strengthen health technology assessment (HTA) across Member States, Leela Barham attempts to assess and benchmark the resources currently d
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh